binx health Continues National Expansion of Onsite Test and Treat on Heels of Alarming WHO Report
2024年7月25日 - 2:14AM
ビジネスワイヤ(英語)
WHO Cites “Pressing Need” for Affordable and Reliable
Point-of-Care Technologies
“Global HIV, viral hepatitis epidemics and sexually transmitted
infections (STIs) continue to pose significant public health
challenges, causing 2.5 million deaths each year,” according to a
new WHO report. The report found four curable STIs -- chlamydia,
gonorrhea, syphilis and trichomoniasis -- are responsible for more
than 1 million infections daily among adults between ages 15 and
49, and binx health is continuing its strategy of expanding access
to rapid onsite testing for chlamydia and gonorrhea, which are the
most common reportable STI infections in the USA.
“There is a pressing need for affordable rapid multiplex
platforms that can simultaneously diagnose multiple pathogens, and
for reliable point-of-care technologies appropriate for use in
health care settings with no or limited access to a laboratory,”
said the WHO.
“We’re excited by the adds to our commercial team and bringing
on our fifth distribution partner in the coming days,” said Jeffrey
Luber, binx health CEO. “This will bring our commercial footprint
nationally to well over 1,200 as we continue to see clinics convert
from multi-day wait times to rapid answers onsite for both male and
female populations through binx. The future is point-of-care and
we’re excited to be leading the charge in sexual health.”
The binx® io molecular point-of-care system continues to be the
only FDA-cleared, CLIA-waived molecular testing platform that can
test both males and females for chlamydia and gonorrhea in about
thirty minutes at levels of accuracy comparable to
central-laboratory testing, consistent with the WHO’s
call-to-action. Using urine specimens from males and clinician- or
self-collected vaginal swabs from females, the binx platform is
seeing broad adoption across market verticals and clinic types.
Unlike traditional test workflows, results are available with binx
in minutes rather than days, enabling clinicians to have
conversations with patients who test positive while they are still
in the clinic—preventing loss to follow up and empiric antibiotic
prescribing.
“A powerful tool in achieving the WHO’s ambitious STI screening
goals is to arm our providers with a point-of-care platform that
can lead to treatment guidance for all populations coming to us,
before the patient leaves our clinic,” said Melissa Reed, CEO of
Planned Parenthood Keystone, Warminster PA. “Only binx offers a
platform with this ability, furthering WHO’s goal of health equity
and inclusion of everyone regardless of gender and sexual
orientation. The binx platform’s ability to test both female
vaginal swabs and male urine specimens give us this broad
ability.”
The WHO report further emphasized the importance of access to
STI testing strategies and strengthening efforts for those at
higher risk of infection including sex workers, men who have sex
with men, transgender people, adolescents in some settings and
pregnant women. Point-of-care platforms that can rapidly test both
males and females remain critical in the tool set of clinics when
selecting a solution for such broad populations.
“Having served in leadership roles with both Thermo Fisher and
Abbott Diagnostics, I had the opportunity to see up close the
market need for male/female rapid onsite testing that connects to
EHR,” said Michael Karsonovich, binx health, Chief Commercial
Officer. “I joined binx due to the market need for better solutions
as a key driver to stem the tide of infection spread. Given the
demand we’re seeing in the market and the strength of our
manufacturing and distribution relationships, I’m heartened by the
strong role we can play in addressing the concerns recently raised
by the WHO.”
With global manufacturing in the US, Europe and APAC, and the
relationships binx has built with the best commercial distribution
partners in the industry, the company continues to lead the market
in scalable, low cost-of-goods solutions for the millions of people
who need them. Manufacturing partners including Harmac Medical
Products’ Ireland division, which has helped arm binx with strides
in capacity and low COGS to meet rising demand.
“Our vision at Harmac Medical Products is ‘changing the lives of
patients, employees and communities in which we work’. We are
thrilled to be working with binx to manufacture a product that
upholds these values and has the ability to impact patient outcomes
given rising demand,” said John Somers, President and CEO of Harmac
Medical Products. “The ability to partner with binx and advance the
manufacture of their critically important product for public health
perfectly fits with Harmac’s manufacturing expertise and we look
forward to being part of the solution of helping to stem the STI
epidemic globally.”
About binx health
binx health® is a healthcare technology and diagnostics company
focused on innovating solutions to improve routine testing and
convenience, providing timely results to improve patient care. The
binx io point-of-care molecular platform is the first ever
FDA-cleared, CLIA-waived point-of-care system for the detection of
chlamydia and gonorrhea in both males (urine) and females (vaginal
swab) that provides results in about thirty minutes with
performance comparable to central labs. The binx io platform is
highly flexible, easy to use, and enables rapid testing and
treatment in a single patient visit. For more information, visit
https://mybinxhealth.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724908087/en/
Mike Geller Prosek Partners mgeller@prosek.com